 NEWARK, Calif., May 24, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq:PTGX today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor IL-23R antagonist peptide. 